Design Therapeutics (DSGN)
(Delayed Data from NSDQ)
$5.29 USD
-0.12 (-2.22%)
Updated Aug 27, 2025 04:00 PM ET
After-Market: $5.30 +0.01 (0.19%) 5:48 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
DSGN 5.29 -0.12(-2.22%)
Will DSGN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DSGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DSGN
Design Therapeutics (DSGN) Upgraded to Buy: Here's Why
Wall Street Analysts See a 31.33% Upside in Design Therapeutics (DSGN): Can the Stock Really Move This High?
DSGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for DSGN
Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference | DSGN Stock News
Stochastic Reached Overbought appears for DSGN after 4.04% move
The technical outlook for DSGN is unchanged after it falls 1.14% on August 25
NR7 appears for DSGN after 2.14% move
DSGN forms 180 Bullish Setup on August 21